AllI · Sterile fill-finish capacityII · Stoppers, syringes & drug-contact componentsIII · Pharmaceutical glass & vialsIV · Bioprocessing consumables & resinsV · API & small-molecule reshoringVI · CDMO capacity & the China exodusVII · Peptide & oligonucleotide manufacturingVIII · Sterile injectables & shortage economicsIX · Analytical instruments & QC releaseX · Private giants & exposure vehicles
| Ticker | Name | Tier ↓ | Quote | Mkt cap | 6M | Chokepoints |
|---|---|---|---|---|---|---|
| LLY | Eli Lilly and Company | core | $1123.00-0.1% | $1.0T | +14.0% | fill-finish |
| LZAGY | Lonza Group AG (unsponsored ADR) | core | $65.61-1.2% | $41.9B | +8.1% | fill-finish · api-reshoring · cdmo-capacity · peptides-oligos · private-giants |
| NVO | Novo Nordisk A/S | core | $44.01-1.2% | $195.0B | +15.9% | fill-finish · private-giants |
| TMO | Thermo Fisher Scientific Inc. | core | $603.18-0.4% | $180.0B | +29.9% | fill-finish · bioprocessing · api-reshoring · cdmo-capacity · instruments-qc |
| FUJIY | FUJIFILM Holdings Corporation (ADR) | watch | $10.37+0.8% | $26.7B | +11.0% | fill-finish · cdmo-capacity |
| SIMTRA | Simtra BioPharma Solutions | speculative | private | — | via — | fill-finish |
Quote shows the latest price and daily change; the 6M column is the total return over that window. Quotes delayed up to 15 minutes; tiers are editorial conviction, not ratings. Click a column header to sort.